Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

LRRK2 in Parkinson's disease: protein domains and functional insights.

Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA.

Trends Neurosci. 2006 May;29(5):286-93. Epub 2006 Apr 17. Review.

PMID:
16616379
2.

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Gandhi PN, Chen SG, Wilson-Delfosse AL.

J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949. Review.

4.

Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.

Kramer T, Lo Monte F, Göring S, Okala Amombo GM, Schmidt B.

ACS Chem Neurosci. 2012 Mar 21;3(3):151-60. doi: 10.1021/cn200117j. Epub 2012 Jan 18. Review.

5.

Contribution of GTPase activity to LRRK2-associated Parkinson disease.

Tsika E, Moore DJ.

Small GTPases. 2013 Jul-Sep;4(3):164-70. doi: 10.4161/sgtp.25130. Epub 2013 Jun 10. Review.

6.

Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.

Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z.

J Neurochem. 2007 Oct;103(1):238-47. Epub 2007 Jul 10.

7.

[Advance of the study on LRRK2 gene in Parkinson's disease].

Zhang Y, Chen S.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):657-9. Review. Chinese.

PMID:
19065525
8.

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. Epub 2005 Nov 3.

9.

The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, Maric D, Jaffe H, Cookson MR.

Biochem J. 2012 Aug 15;446(1):99-111. doi: 10.1042/BJ20120637.

10.

LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Xiong Y, Dawson VL, Dawson TM.

Biochem Soc Trans. 2012 Oct;40(5):1074-9. Review.

11.

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.

Whaley NR, Uitti RJ, Dickson DW, Farrer MJ, Wszolek ZK.

J Neural Transm Suppl. 2006;(70):221-9. Review.

PMID:
17017533
12.

Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.

Bravo-San Pedro JM, Gómez-Sánchez R, Niso-Santano M, Pizarro-Estrella E, González-Polo RA, Fuentes JM.

Biochem Soc Trans. 2012 Oct;40(5):1129-33. Review.

PMID:
22988877
13.

Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.

Gómez-Suaga P, Fdez E, Fernández B, Martínez-Salvador M, Blanca Ramírez M, Madero-Pérez J, Rivero-Ríos P, Fuentes JM, Hilfiker S.

Neuropharmacology. 2014 Oct;85:45-56. doi: 10.1016/j.neuropharm.2014.05.020. Epub 2014 May 24. Review.

PMID:
24863040
14.

GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ.

PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.

15.

LRRK2 in Parkinson's disease: biochemical functions.

Anand VS, Braithwaite SP.

FEBS J. 2009 Nov;276(22):6428-35. doi: 10.1111/j.1742-4658.2009.07341.x. Epub 2009 Oct 5. Review.

16.

[Clinical molecular genetics for PARK8 (LRRK2)].

Tomiyama H, Hatano T, Hattori N.

Brain Nerve. 2007 Aug;59(8):839-50. Review. Japanese.

PMID:
17713120
17.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
18.

The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Moore DJ.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S92-8. doi: 10.1016/j.parkreldis.2008.04.010. Epub 2008 Jul 7. Review.

PMID:
18602856
19.

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Greggio E, Cookson MR.

ASN Neuro. 2009 Apr 14;1(1). pii: e00002. doi: 10.1042/AN20090007. Review.

20.

The small GTPase activity of the ROC domain from LRRK2, a Parkinson's disease related protein.

Fu QS, Song AX, Li SX, Hu HY.

Protein Pept Lett. 2009;16(12):1442-6.

PMID:
20001906

Supplemental Content

Support Center